Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing safety surveillance of Gardasil and Gardasil 9 in a Chinese female cohort
CTR20210666Phase 4Active
- Sponsor
- Merck & Co.
- Start
- Apr 2021
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of recombinant human papillomavirus 9-valent vaccine, qHPV vaccine in human papillomavirus infection, Cervical Cancer (CC), Vulval carcinoma, vaginal cancer, anal cancer, sponsored by Merck & Co.. Started Apr 2021; status: active.
02
Drugs
recombinant human papillomavirus 9-valent vaccineqHPV vaccine
03
Conditions
human papillomavirus infectionCervical Cancer (CC)Vulval carcinomavaginal canceranal cancer
Beyond the preview
Go deeper on CTR20210666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210666.